$1.49 Billion is the total value of Rock Springs Capital Management LP's 133 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 12.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $56,893,000 | +73.7% | 465,000 | +74.0% | 3.81% | +85.4% |
| AET | Buy | AETNA INC NEW | $54,688,000 | +7.6% | 441,000 | +0.2% | 3.66% | +14.9% |
| MRK | Buy | MERCK & CO INC | $44,153,000 | +20.4% | 750,000 | +27.7% | 2.96% | +28.6% |
| GWPH | Buy | GW PHARMACEUTICALS PLCads | $39,783,000 | -7.8% | 356,000 | +9.5% | 2.66% | -1.6% |
| ACHC | Buy | ACADIA HEALTHCARE COMPANY IN | $38,313,000 | -16.4% | 1,157,500 | +25.2% | 2.56% | -10.7% |
| RDUS | Buy | RADIUS HEALTH INC | $34,617,000 | -28.3% | 910,250 | +2.0% | 2.32% | -23.4% |
| CI | Buy | CIGNA CORPORATION | $33,614,000 | +12.9% | 252,000 | +10.3% | 2.25% | +20.5% |
| ISRG | Buy | INTUITIVE SURGICAL INC | $30,440,000 | -6.7% | 48,000 | +6.7% | 2.04% | -0.4% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $29,854,000 | +14.7% | 1,100,000 | +8.3% | 2.00% | +22.5% |
| ARDX | Buy | ARDELYX INC | $28,400,000 | +11.1% | 2,000,000 | +1.3% | 1.90% | +18.6% |
| UNH | New | UNITEDHEALTH GROUP INC | $26,407,000 | – | 165,000 | +100.0% | 1.77% | – |
| BMY | Buy | BRISTOL MYERS SQUIBB CO | $26,298,000 | +95.1% | 450,000 | +80.0% | 1.76% | +108.3% |
| COLL | Buy | COLLEGIUM PHARMACEUTICAL INC | $24,912,000 | -16.3% | 1,600,000 | +3.6% | 1.67% | -10.6% |
| LLY | Buy | LILLY ELI & CO | $23,904,000 | +7.9% | 325,000 | +17.8% | 1.60% | +15.2% |
| MDCO | Buy | MEDICINES CO | $23,741,000 | -7.6% | 699,500 | +2.7% | 1.59% | -1.4% |
| SHPG | Buy | SHIRE PLCsponsored adr | $23,376,000 | -9.0% | 137,200 | +3.5% | 1.56% | -2.9% |
| PCRX | Buy | PACIRA PHARMACEUTICALS INC | $23,030,000 | +33.5% | 713,000 | +41.5% | 1.54% | +42.6% |
| PEN | Buy | PENUMBRA INC | $18,853,000 | -6.9% | 295,500 | +10.9% | 1.26% | -0.6% |
| INCY | Buy | INCYTE CORP | $16,946,000 | +14.8% | 169,000 | +8.0% | 1.13% | +22.6% |
| PRAH | Buy | PRA HEALTH SCIENCES INC | $16,536,000 | +15.7% | 300,000 | +18.6% | 1.11% | +23.5% |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $15,374,000 | -2.8% | 4,991,500 | +0.7% | 1.03% | +3.8% |
| WMGI | Buy | WRIGHT MED GROUP N V | $15,328,000 | +1.9% | 667,000 | +8.8% | 1.03% | +8.8% |
| PRTA | Buy | PROTHENA CORP PLC | $15,224,000 | -17.6% | 309,500 | +0.5% | 1.02% | -12.0% |
| AMGN | Buy | AMGEN INC | $14,109,000 | -10.0% | 96,500 | +2.7% | 0.94% | -4.0% |
| CHRS | Buy | COHERUS BIOSCIENCES INC | $13,639,000 | +8.9% | 484,500 | +3.6% | 0.91% | +16.3% |
| JAZZ | Buy | JAZZ PHARMACEUTICALS PLC | $13,487,000 | +3.8% | 123,700 | +15.6% | 0.90% | +10.8% |
| WLTW | Buy | WILLIS TOWERS WATSON PUB LTD | $13,451,000 | +73.2% | 110,000 | +88.0% | 0.90% | +84.8% |
| RARX | New | RA PHARMACEUTICALS INC | $12,547,000 | – | 826,000 | +100.0% | 0.84% | – |
| EW | Buy | EDWARDS LIFESCIENCES CORP | $11,291,000 | -9.3% | 120,500 | +16.7% | 0.76% | -3.1% |
| RARE | Buy | ULTRAGENYX PHARMACEUTICAL IN | $11,232,000 | +7.7% | 159,750 | +8.7% | 0.75% | +15.0% |
| DERM | Buy | DERMIRA INC | $10,998,000 | -8.4% | 362,600 | +2.1% | 0.74% | -2.3% |
| HOLX | Buy | HOLOGIC INC | $10,632,000 | +8.4% | 265,000 | +5.0% | 0.71% | +15.6% |
| NVTA | Buy | INVITAE CORP | $9,528,000 | +22.2% | 1,200,000 | +34.8% | 0.64% | +30.5% |
| EVHC | New | ENVISION HEALTHCARE CORP | $9,177,000 | – | 145,000 | +100.0% | 0.61% | – |
| MRUS | Buy | MERUS N V | $8,444,000 | +31.6% | 400,000 | +4.4% | 0.56% | +40.5% |
| PRTK | Buy | PARATEK PHARMACEUTICALS INC | $8,093,000 | +23.8% | 525,500 | +4.6% | 0.54% | +32.2% |
| BGNE | Buy | BEIGENE LTDsponsored adr | $8,045,000 | +16.1% | 265,000 | +17.8% | 0.54% | +23.7% |
| REGN | Buy | REGENERON PHARMACEUTICALS | $7,158,000 | +4.7% | 19,500 | +14.7% | 0.48% | +11.9% |
| LGND | Buy | LIGAND PHARMACEUTICALS INC | $7,113,000 | +7.2% | 70,000 | +7.7% | 0.48% | +14.4% |
| ATHN | Buy | ATHENAHEALTH INC | $6,599,000 | +14.4% | 62,750 | +37.2% | 0.44% | +22.1% |
| ASND | Buy | ASCENDIS PHARMA A Ssponsored adr | $6,578,000 | +9.1% | 325,000 | +8.3% | 0.44% | +16.4% |
| EXAS | Buy | EXACT SCIENCES CORP | $6,024,000 | -25.4% | 450,900 | +3.7% | 0.40% | -20.4% |
| ACHN | Buy | ACHILLION PHARMACEUTICALS IN | $5,679,000 | -46.7% | 1,375,000 | +4.5% | 0.38% | -43.1% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $5,264,000 | -50.5% | 191,900 | +10.9% | 0.35% | -47.1% |
| FGEN | Buy | FIBROGEN INC | $5,136,000 | +6.3% | 240,000 | +2.8% | 0.34% | +13.5% |
| STE | Buy | STERIS PLC | $4,380,000 | +49.8% | 65,000 | +62.5% | 0.29% | +60.1% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $3,765,000 | -26.8% | 757,500 | +9.0% | 0.25% | -21.7% |
| CDTX | Buy | CIDARA THERAPEUTICS INC | $3,120,000 | +9.0% | 300,000 | +20.0% | 0.21% | +16.8% |
| NBRV | Buy | NABRIVA THERAPEUTICS AGsponsored adr | $3,124,000 | +4.0% | 525,000 | +23.2% | 0.21% | +11.2% |
| ARIA | Buy | ARIAD PHARMACEUTICALS INC | $3,110,000 | +809.4% | 250,000 | +900.0% | 0.21% | +890.5% |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $2,901,000 | -37.7% | 94,500 | +36.0% | 0.19% | -33.6% |
| TTPH | Buy | TETRAPHASE PHARMACEUTICALS I | $2,813,000 | +10.9% | 698,000 | +5.4% | 0.19% | +18.2% |
| EXEL | Buy | EXELIXIS INC | $2,609,000 | +63.2% | 175,000 | +40.0% | 0.18% | +75.0% |
| MDGL | Buy | MADRIGAL PHARMACEUTICALS INC | $2,606,000 | +226.2% | 174,891 | +177.6% | 0.17% | +248.0% |
| SCYX | Buy | SCYNEXIS INC | $2,424,000 | -1.3% | 760,000 | +19.7% | 0.16% | +5.2% |
| ZBH | New | ZIMMER BIOMET HLDGS INC | $2,178,000 | – | 21,100 | +100.0% | 0.15% | – |
| HQY | New | HEALTHEQUITY INC | $2,026,000 | – | 50,000 | +100.0% | 0.14% | – |
| BLUE | Buy | BLUEBIRD BIO INC | $1,758,000 | +29.6% | 28,500 | +42.5% | 0.12% | +38.8% |
| New | THERAVANCE BIOPHARMA INCnote 3.250%11/0 | $1,713,000 | – | 1,500,000 | +100.0% | 0.12% | – | |
| MYOV | New | MYOVANT SCIENCES LTD | $1,115,000 | – | 89,600 | +100.0% | 0.08% | – |
| VRX | Buy | VALEANT PHARMACEUTICALS INTL | $1,037,000 | -38.4% | 71,400 | +4.1% | 0.07% | -34.9% |
| LIFE | Buy | ATYR PHARMA INC | $1,021,000 | -26.0% | 475,000 | +9.6% | 0.07% | -20.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.